SCHEMBL17860267

SCHEMBL17860267

NCCC(=O)Nc1ccc(N2C(=O)C=CC2=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 2/20 0.51
HSP90AA1 P07900 4/20 0.50
MGLL Q99685 6/20 0.47
FAAH O00519 3/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALDH1A1 P00352 3/20 0.47
PKM P14618 2/20 0.47
MAPK1 P28482 2/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 2/20 0.47
MAPT P10636 2/20 0.47
XBP1 P17861 1/20 0.47
CCR6 P51684 1/20 0.47
DDAH1 O94760 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
LTA4H P09960 2/20 0.44
TLR9 Q9NR96 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134832 0.84 TP53 (0.60) HSP90AA1MGLLFAAHSMN1; SMN2NPSR1
SCHEMBL20287892 0.81 TERT (0.41) TERTHSP90AA1MGLLSMN1; SMN2NPSR1
SCHEMBL12505801 0.78 MGLL (0.56) HSP90AA1MGLLFAAHNPSR1ALDH1A1
SCHEMBL5580375 0.78 MGLL (0.60) HSP90AA1MGLLFAAHSMN1; SMN2NPSR1
SCHEMBL8194022 0.76 HSP90AA1 (0.59) HSP90AA1MGLLFAAHNPSR1ALDH1A1
SCHEMBL8505932 0.75 SCN2A (0.63) HSP90AA1MGLLFAAHSMN1; SMN2NPSR1
SCHEMBL19150356 0.74 CYP1A1 (0.67) TERTSMN1; SMN2NPSR1ALDH1A1MAPK1
SCHEMBL4400398 0.74 L3MBTL1 (0.71) SMN1; SMN2ALDH1A1HPGDHTTMAPT
SCHEMBL8404261 0.73 DDAH1 (0.59) HSP90AA1MGLLFAAHSMN1; SMN2NPSR1
SCHEMBL12268629 0.73 DDAH1 (0.59) HSP90AA1MGLLFAAHSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 EP disclosed
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-27 US disclosed
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-11-19 US disclosed
EP-4406606-A2 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G Bayer Pharma Aktiengesellschaft (DE) 2024-07-31 EP disclosed
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-02-09 US disclosed
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-02-09 US disclosed
US-11123439-B2 Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-09-21 US disclosed
US-11071788-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2021-07-27 US disclosed
US-10744205-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-08-18 US disclosed
EP-3086814-B1 DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) Bayer Pharma AG (DE) 2020-06-24 EP disclosed
US-10022453-B2 Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-17 US disclosed
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES Bayer Pharma AG (DE) 2018-07-05 US disclosed
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES Bayer Pharma AG (DE) 2018-07-05 US disclosed
US-20180169256-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-06-21 US disclosed
US-20180169256-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-06-21 US disclosed
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 US disclosed
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-01-18 US disclosed
US-20160346402-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-01 US disclosed
US-20160346402-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-12-01 US disclosed
WO-2016096610-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10744205-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies KIF23, KIF2C, KIF18A TERT 4832/4885HSP90AA1 1162/4885MGLL 4664/4885
US-11123439-B2 Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups KIFC1, KIF2C, KIF5B TERT 4796/4885HSP90AA1 2035/4885MGLL 4708/4885
US-10022453-B2 Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) KIF5B, KIF23, KIF2C TERT 4875/4885HSP90AA1 1301/4885MGLL 4657/4885
US-11071788-B2 Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies KIF23, KIF5B, KIF2C TERT 4876/4885HSP90AA1 1659/4885MGLL 4836/4885
US-20180185510-A1 ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES KIF23, KIF5B, KIF2C TERT 4863/4885HSP90AA1 1220/4885MGLL 4704/4885
US-20180015176-A1 ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES TNFSF11, TNFRSF9, CD40 TERT 4511/4885HSP90AA1 2556/4885MGLL 4430/4885
US-20160346402-A1 ANTIBODY DRUG CONJUGATES (ADCS) WITH KINESIN SPINDEL PROTEIN (KSP) KIF5B, KIF23, KIF2C TERT 4875/4885HSP90AA1 1301/4885MGLL 4657/4885
US-20180169256-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS KIFC1, KIF2C, KIF5B TERT 4796/4885HSP90AA1 2035/4885MGLL 4708/4885
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates KIF18B, KIF18A, KIF5B TERT 3440/4885HSP90AA1 488/4885MGLL 4551/4885
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups KIFC1, KIF2C, KIF5B TERT 4760/4885HSP90AA1 1658/4885MGLL 4646/4885
US-20230039341-A1 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS KIFC1, KIF2C, KIF5B TERT 4796/4885HSP90AA1 2035/4885MGLL 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.